Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation

Chahal J, Gómez-Aristizábal A, Shestopaloff K, et al. · Stem Cells Translational Medicine

Safe at all doses; KOOS pain and quality of life improved at 12 months with the 50-million dose performing best, alongside dose-dependent reductions in synovitis and cartilage catabolic biomarkers.

Population

12 patients with late-stage (KL 3-4) knee OA, phase I/IIa dose-escalation

Intervention

Autologous culture-expanded BM-MSCs at 1, 10, or 50 million cells

Comparator

None (open-label dose escalation)

Limitations

No control arm; n=12; biomarker endpoints are mechanistic, not clinical proof; author industry disclosures.